These latest findings have significant implications for developing eEF1A-targeting therapeutics, as the enzyme’s overexpression in cancer cells makes it an attractive drug target, though potential resistance mechanisms involving mutations in eEF1A or the hijacking of the degradation pathway must be considered. This evidence concerns the gene EEF1A1 and cancer.